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ABSTRACT
Objective: To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for
adults with chronic hemiparesis and assess long-term safety and efficacy of repeated injections.
Methods: In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study fol-
lowed by a 1-year open-label, multiple-cycle extension, adults$6months after stroke/brain injury
received one lower limb injection (abobotulinumtoxinA 1,000 U, abobotulinumtoxinA 1,500 U,
placebo) followed by #4 open-label cycles (1,000, 1,500 U) at $12-week intervals. Efficacy
measures included Modified Ashworth Scale (MAS) in gastrocnemius–soleus complex (GSC;
double-blind primary endpoint), physician global assessment (PGA), and comfortable barefoot
walking speed. Safety was the open-label primary endpoint.
Results: After a single injection, mean (95% confidence interval) MAS GSC changes from baseline
at week 4 (double-blind, n5 381) were as follows:20.5 (20.7 to20.4) (placebo, n5 128),20.6
(20.8 to 20.5) (abobotulinumtoxinA 1,000 U, n 5 125; p5 0.28 vs placebo), and 20.8 (20.9 to
20.7) (abobotulinumtoxinA 1,500 U, n 5 128; p 5 0.009 vs placebo). Mean week 4 PGA scores
were as follows: 0.7 (0.5, 0.9) (placebo), 0.9 (0.7, 1.1) (1,000 U; p 5 0.067 vs placebo), and 0.9
(0.7, 1.1) (1,500 U; p 5 0.067); walking speed was not significantly improved vs placebo. At
cycle 4, week 4 (open-label), meanMASGSC change reached21.0. Incremental improvements in
PGA and walking speed occurred across open-label cycles; by cycle 4, week 4, mean PGA was
1.9, and walking speed increased 125.3% (17.5, 33.2), with 16% of participants walking .0.8
m/s (associated with community mobility; 0% at baseline). Tolerability was good and consistent
with the known abobotulinumtoxinA safety profile.
Conclusions: In chronic hemiparesis, single abobotulinumtoxinA (Dysport Ipsen) administration
reduced muscle tone. Repeated administration over a year was well-tolerated and improved walk-
ing speed and likelihood of achieving community ambulation.
Clinicaltrial.gov identifiers: NCT01249404, NCT01251367.
Classification of evidence: The double-blind phase of this study provides Class I evidence that for
adults with chronic spastic hemiparesis, a single abobotulinumtoxinA injection reduces lower
extremity muscle tone. Neurology® 2017;89:2245–2253
GLOSSARY
ANCOVA 5 analysis of covariance; BoNT-A 5 botulinum toxin type A; CI 5 confidence interval; CS 5 coefficients of muscle
shortening; EQ-5D 5 European Quality of Life; GSC 5 gastrocnemius–soleus complex; ITT 5 intent-to-treat; MAS 5 Mod-
ified Ashworth Scale; PGA 5 physician global assessment; QoL 5 quality of life; SAE 5 serious adverse event; SF-36 5
Short-Form Health Survey; TBI 5 traumatic brain injury; TEAE 5 treatment-emergent adverse event.
Hemiparesis from acquired brain injury can impair mobility, related to abnormal passive and active
antagonist muscle resistance.1,2 In chronic hemiparesis, walking speed stabilizes at a low plateau level,
inadequate for sustainable community ambulation.3,4 Slow walking speed and inability to ambulate
in the community represents a significant health issue, associated with accelerated health decline.5,6
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Intramuscular injection of botulinum toxin
type A (BoNT-A), a neurotoxin produced by
Clostridium botulinum bacteria,7 produces
muscle relaxation for 12–16 weeks or longer
and is an effective treatment for muscle over-
activity in spastic paresis.8–13 While abobotuli-
numtoxinA (Dysport; IpsenPharma, Wrexham,
UK) reduces muscle tone and improves
spasticity-related features in upper and lower
limb muscles, long-term safety of repeated
lower limb injections and concomitant effect
on walking speed in hemiparesis have not
been explored.8–13
We evaluated efficacy and safety of abobotu-
linumtoxinA in participants with chronic hemi-
paresis causing walking impairment, from
a double-blind, single-cycle study followed by
an open-label, repeated-cycle extension.
METHODS Primary research question. The double-blind
study asked whether abobotulinumtoxinA is effective at reduc-
ing lower extremity muscle tone, measured using the Modified
Ashworth Scale (MAS) score. This study provides Class I evidence
that for adults with chronic spastic hemiparesis, a single abobo-
tulinumtoxinA injection reduces lower extremity muscle tone.
Standard protocol approvals, registrations, and partici-
pant consents. The research protocol and all study documents
were approved by an independent ethics committee. The study
was conducted in accordance with the Declaration of Helsinki
and the International Conference on Harmonisation Consoli-
dated Guidelines on Good Clinical Practice. Written informed
consent was obtained prior to participants entering the study
(Clinical Trial identifiers, double-blind NCT01249404; open-
label NCT01251367).
Study population. Inclusion criteria were ambulatory partici-
pants aged 18–80 years with spastic hemiparesis causing gait
dysfunction; comfortable barefoot walking speed 0.1–0.8 m/s,
measured on a 10-m walking speed test without walking aids; 1
clinically defined stroke episode or brain trauma$6 months prior
to enrollment; MAS score $2 in gastrocnemius–soleus complex
(GSC; measured with knee extended) in toxin-naive participants
(no previous BoNT-A injection in affected lower limb) or $3 in
toxin non-naive participants ($4 months after last BoNT-A
injection); and GSC spasticity angle $58 (Tardieu Scale).14
Exclusion criteria were major limitation in passive range of
motion at hip, knee, or ankle; known sensitivity to BoNT or
abobotulinumtoxinA excipients; pregnancy; and severe cognitive
impairment that interfered with consent provision. No stan-
dardized physiotherapy regimen was associated with this protocol,
but community physiotherapy initiated before study had to
remain unchanged to week 4 and whenever possible until study
end. No physiotherapy was initiated ,4 weeks prior to study or
during the first 4 study weeks.
Study design. This was a phase III, multicenter, prospective,
double-blind, randomized, placebo-controlled, single-treatment-
cycle study in adults with chronic hemiparesis, followed by
a phase III, multicenter, prospective, open-label, multiple-cycle
extension. Fifty-two centers across Australia, Belgium, Czech
Republic, France, Hungary, Italy, Poland, Portugal, Russia,
Slovakia, and the United States participated.
The double-blind study consisted of a single injection of abo-
botulinumtoxinA 1,000 U, 1,500 U, or placebo into both soleus
and gastrocnemius muscles and $1 other (investigator-selected)
lower limb muscle (e-Methods at Neurology.org). For the open-
label extension, participants were offered abobotulinumtoxinA for
#4 treatment cycles at $12-week intervals, over #18 months. In
both studies, selected muscles were targeted using electrical stimu-
lation. At open-label cycle 1, all participants received 1,500 U
except participants who experienced treatment-emergent adverse
events (TEAEs) during the double-blind phase, which the investi-
gator considered posed unacceptable risk, who received 1,000 U.
For subsequent cycles, abobotulinumtoxinA 1,000 or 1,500 U
was administered at weeks 12, 16, 20, or 24, based on the inves-
tigator’s judgment. Retreatment was possible at intervals $12
weeks (e-Methods). For cycles 3/4, concomitant 500 U injection
into the upper limb was allowed at the investigator’s discretion,
while keeping the total body dose #1,500 U.
Study objectives. The double-blind study primary objective
was to demonstrate single abobotulinumtoxinA injection efficacy
vs placebo in the lower extremity; safety was a secondary objective.
The open-label study primary objective was to assess long-term
safety of repeated abobotulinumtoxinA injections; long-term effi-
cacy was a secondary objective.
Outcome measures. The double-blind primary endpoint was
GSC muscle tone (MAS knee extended) change from baseline
after 4 weeks. Secondary endpoints, also measured after 4 weeks,
were physician global assessment (PGA) score (9-point scale; 24
[markedly worse] to 4 [markedly improved]) assessed by an
investigator different from the one assessing MAS; and 10-m
comfortable barefoot walking speed without walking aids
change from baseline. Exploratory endpoints included soleus
muscle tone (MAS knee flexed) mean change from baseline,
spasticity (Tardieu Scale; angle of arrest XV1, angle of catch XV3,
spasticity grade Y), range of active ankle dorsiflexion (XA), mea-
sured knee flexed and extended,14 and Short-Form Health Survey
(SF-36) and European Quality of Life (EQ-5D) questionnaires.
Safety assessment included TEAEs elicited by direct, nonleading
questioning and spontaneous reports; laboratory measures;
vital signs; ECG analysis; and neutralizing antibodies analysis
(e-Methods). Identical safety and efficacy endpoints were assessed
throughout the open-label study. This report focuses on key
efficacy endpoints of muscle tone, PGA, comfortable barefoot
walking speed, spasticity, and active range of motion.3,14
Double-blind study randomization. Participants were ran-
domized (1:1:1) using a block design to receive abobotulinum-
toxinA 1,000 U, 1,500 U, or placebo and stratified by toxin
baseline status (naive and non-naive; e-Methods).
Statistical analysis. Sample size calculation. For the double-
blind study, 156 randomized participants (n 5 52 per treat-
ment group) were necessary to demonstrate significance on MAS
change from baseline to week 4 in GSC (primary endpoint) with
a 2-sided comparison-wise type I error rate at 0.025% and 90%
power, assuming mean MAS changes of 20.9 with active treat-
ments and 20.4 with placebo, common SD of 0.7, and 3%
dropout rate. To meet long-term safety objectives, a sample size of
348 randomized participants was considered necessary (assuming
97% double-blind participants would enter the open-label study
and a 5% dropout rate at each subsequent cycle). Centers that
recruited fewer than 6 participants were considered small centers
and were pooled with one another (e-Methods).
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Double-blind phase. The primary population for efficacy
analyses was the intent-to-treat (ITT) population, defined as all
randomized participants who received $1 study medication
injection, with baseline and week 4 MAS scores.
MAS consists of 6 grades: 0, 1, 11, 2, 3, or 4. For quanti-
tative analyses, 11 was considered as 2 and higher numeric scores
were incremented by 1, giving a 6-point MAS range (0–5). For
the primary endpoint, mean data were tested using 2 contrast
analyses within a single mixed-effect analysis of covariance (AN-
COVA) model, controlled for baseline MAS score, baseline
BoNT treatment status, and center, all as fixed factors (post
hoc analysis was conducted using rank transform and propor-
tional odds models to address possible lack of data normality
[e-Results]). To control family-wise type I error rate, a 2-step
Hochberg method (e-Methods) was applied to demonstrate supe-
riority of either abobotulinumtoxinA dose to placebo. For PGA,
identical analyses were performed on mean week 4 values. Post
hoc analysis using ranked PGA scores and proportional odds
analysis (e-Results) was undertaken to restore power. For other
endpoints, a single, mixed-effect ANCOVAmodel was performed.
Open-label phase. Descriptive statistics were performed for all
efficacy and safety endpoints. Post hoc analyses by subgroup tested
whether walking speed changes differed depending on time since
lesion and concomitant physiotherapy, and whether participants
changed gait speed range categories, reported according to functions
of household ambulation (,0.4 m/s), limited community mobility
(0.4–0.8 m/s), and full community mobility (.0.8 m/s).15 Addi-
tional post hoc analyses were performed using Pearson correlation
coefficients estimated by treatment group (baseline–study end)
exploring linear relationships between (1) time since lesion and
walking speed change; and (2) composite XA (XA against GSC1 XA
against soleus) and walking speed. Additional post hoc analysis
compared 10-m walking speed change at week 4 vs 12 across cycles
using a model for repeated measures.
Clinical trial data disclosure Results of the double-blind study
(NCT01249404) were posted on the EudraCT website on August
1, 2015. Results of the open-label extension (NCT01251367) were
posted on the EudraCT website on March 31, 2017.
RESULTS Study population characteristics. Of 381
double-blind phase participants (128 placebo, 125
abobotulinumtoxinA 1,000 U, 128 abobotuli-
numtoxinA 1,500 U; ITT population; study initia-
tion March 2011; completion May 2014), 352
continued in the open-label phase (figure 1; study
initiation June 2011; completion April 2015). Par-
ticipant characteristics are presented in table 1.
Approximately 60% of participants underwent con-
comitant physiotherapy, including during the open-
label phase. To appreciate loss of gastrocnemius and
soleus extensibility, baseline coefficients of muscle
shortening (CS) were retrospectively calculated
(CS 5 [XN 2 XV1]/XN, where XN is the normal
expected amplitude [1158 GSC; 1208 soleus]).16
Mean (SD) baseline CS were 23.7% (8.5) in GSC
and 20.6% (7.9) in soleus. Mean treatment exposure
duration (2 studies combined) was 54 weeks; table e-1
lists doses injected per muscle.
Efficacy of a single injection (double-blind study). The
main efficacy results after a single injection are
presented in table 2. At week 4, a single injection of
abobotulinumtoxinA 1,500 U reduced MAS GSC to
a greater extent than placebo (p 5 0.009), with no
significant difference seen between abobotulinumtox-
inA 1,000 U and placebo (p 5 0.28). GSC tone
reduction vs placebo at week 4 in the 1,500 U group
was maintained at week 12 (1,000 U not statistically
different). Tone reduction occurred in soleus with
both doses at weeks 4 and 12 (table e-2). Exploratory
analysis of treatment-by-center interaction is pre-
sented in e-Results.
According to the planned analysis, neither dose
was significantly more effective than placebo at week
4 for PGA (table e-2). However, week 4 PGA distri-
bution was heavily skewed, undermining the assump-
tion of normality necessary to support a statistically
valid and powerful ANCOVA. Exploratory analysis
using ranked PGA scores showed both doses were
superior to placebo (table e-2). There was no differ-
ence in comfortable barefoot walking speed change
from baseline among the 3 groups at weeks 4 or 12
(table e-2), nor for quality of life (QoL) scales. For
changes in active range of ankle dorsiflexion and
spasticity (XV1, XV3, Y), see e-Results (figure e-1,
table e-3).
Baseline characteristics were similar in BoNT-A-
naive and non-naive participants, and BoNT-A status
at baseline (naive vs non-naive) did not affect efficacy
outcomes (table e-4). AbobotulinumtoxinA had sim-
ilar efficacy in poststroke and traumatic brain injury
(TBI) participants (table e-5).
Effects of repeated injections (open-label study). From
here, results are presented with doses combined as par-
ticipants could alternate abobotulinumtoxinA doses
between cycles based on clinical need, and because
open-label results were similar across doses. Muscle
tone improvements observed in the double-blind study
(table 2) remained stable from cycle 2 week 4 onwards,
with20.9 from baseline in GSC (figure 2A) and21.1
in soleus. PGA continuously improved from the
double-blind study, reaching 1.9 at cycle 4 week 4
(figure 2B). Comfortable barefoot walking speed pro-
gressively increased across treatment cycles, reaching
125.35% (95% confidence interval 17.48–33.21) at
cycle 4 week 4 from double-blind study baseline
(figure 2C). Greater improvement was observed at
week 12 than week 4 across cycles (figure 2C; p ,
0.001, table e-6). Correlation between time since event
and walking speed improvement suggested the more
recent the event (stroke or TBI), the greater the
improvement (e-Results, tables e-7 and e-8). For
changes in passive, active range of ankle dorsiflexion
and spasticity (XV1, XV3, XA, Y), see e-Results (figure
e-1; table e-3). For QoL, by cycle 4 week 4, there were
mean increases from baseline in SF-36 physical
Neurology 89 November 28, 2017 2247
Figure 1 Participant disposition
aOf the 12 patients in the observational phase, 5 required retreatment and entered cycle 1 and 7 did not require retreatment. Of these 7 patients, 3
withdrew early and 4 completed the study without retreatment. bIncluding 2 participants who entered an observational phase and received no further
abobotulinumtoxinA (ABO) injections during the study. cIn cycles 3 and 4, concomitant treatment of the affected upper limb muscles was allowed.
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component (12.80, SD 6.65) and EQ-5D visual
analogue scale (15.5, SD 21.0).
Time to retreatment. Among participants who received
abobotulinumtoxinA in the double-blind study and
continued in open-label cycle 1, 20.1% were not
considered by the investigator to need reinjection at
week 12 (9.8% were reinjected at week 16, 4.9% at
week 20, 5.4% at week 24 or later). For open-label
cycle 2, 32% were not reinjected at week 12
(16.5% retreated at week 16, 8.8% at week 20, 6.7%
at week 24 or later). For open-label cycle 3, 15.2%
were not reinjected at week 12.
Safety. After a single injection (double-blind study),
TEAE incidence was slightly higher with abobotuli-
numtoxinA than placebo (table 3). Most TEAEs were
mild to moderate and considered unrelated to study
treatment. Overall, TEAEs were most frequently falls,
pain in extremity, and muscle weakness (see e-Results
Table 2 Modified Ashworth Scale gastrocnemius–soleus complex scores for the double-blind phase (intent-to-
treat population)
Efficacy measures Placebo (n 5 128) ABO 1,000 U (n 5 125) ABO 1,500 U (n 5 128)
Baseline mean (SD) 3.9 (0.5) 3.8 (0.5) 3.7 (0.5)
Week 4 mean (SD) 3.4 (0.8) 3.2 (0.9) 3.1 (0.9)
LS mean (95% CI)a 20.5 (20.7 to 20.4) 20.6 (20.8 to 20.5) 20.8 (20.9 to 20.7)
p Value vs placebo — 0.2859 0.0091
Week 12 mean (SD) 3.5 (0.7) 3.4 (0.7) 3.3 (0.9)
LS mean (95% CI)a 20.4 (20.5 to 20.2) 20.4 (20.5 to 20.2) 20.6 (20.7 to 20.4)
p Value vs placebo — 0.9536 0.0324
Abbreviations: ABO 5 abobotulinumtoxinA; CI 5 confidence interval; LS 5 least squares.
a LS means for each treatment group and treatment comparisons, as well as the p values, were obtained from an analysis
of covariance on the change from baseline with treatment, baseline score, botulinum toxin treatment status at baseline,
and center as covariates.
Table 1 Baseline demographics and participant characteristics (intent-to-treat population)
Double-blinda
Open-label,a total
(n 5 352)
Placebo
(n 5 128)
ABO 1,000 U
(n 5 125)
ABO 1,500 U
(n 5 128)
Total
(n 5 381)
Mean age, y (SD) (range)
All participants 51.4 (12.9) (20–79) 53.2 (13.2) (24–77) 53.3 (12.0) (23–77) 52.6 (12.7) (20–79) 53.2 (12.7) (21–80)
Stroke 54.3 (11.5) 55.4 (12.0) 54.9 (10.8) 54.8 (11.4) 55.1 (11.6)
Traumatic brain injury 37.4 (9.7) 38.5 (11.2) 38.3 (13.6) 38.0 (11.0) 39.1 (11.3)
Sex, n (%)
Male 90 (70.3) 87 (69.6) 79 (61.7) 256 (67.2) 239 (67.9)
Female 38 (29.7) 38 (30.4) 49 (38.3) 125 (32.8) 113 (32.1)
Weight, kg (SD) 79.7 (17.9) 79.6 (16.5) 80.1 (14.8) 79.8 (16.4) 79.9 (16.5)
Affected leg, n (%)
Left 74 (57.8) 64 (53.6) 68 (53.1) 209 (54.9) 194 (55.1)
Right 54 (42.2) 58 (46.4) 60 (46.9) 172 (45.1) 158 (44.9)
Cause, n (%)
Stroke 106 (82.8) 109 (87.2) 116 (90.6) 331 (86.9) 309 (87.8)
Traumatic brain injury 22 (17.2) 16 (12.8) 12 (9.4) 50 (13.1) 43 (12.2)
Mean time since event, y (SD)
Stroke 4.2 (3.7) 5.0 (5.5) 4.7 (5.3) 4.6 (4.9) 4.5 (4.8)
Traumatic brain injury 10.6 (13.1) 6.7 (7.4) 8.5 (5.3) 8.8 (10.0) 9.2 (10.1)
Treatment-naive,b n (%) 81 (63.3) 82 (65.6) 80 (62.5) 243 (63.8) 226 (64.2)
Abbreviation: ABO 5 abobotulinumtoxinA.
a Intent-to-treat data are given for the double-blind study and safety population data are given for the open-label study.
bNaive to treatment with any form of botulinum toxin administered to the affected lower limb.
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and table e-9). Six participants (2 per group) with-
drew due to TEAEs: pulmonary embolism, loss of
consciousness (placebo); arthralgia, pancreatic carci-
noma (abobotulinumtoxinA 1,000 U); and generalized
muscle weakness (abobotulinumtoxinA 1,500 U).
Twenty serious adverse events (SAEs) occurred in
17 participants, equally distributed between groups.
There were 2 deaths (1 pulmonary embolism, 1
“natural causes”; both placebo). One SAE was sug-
gestive of remote toxin spread (generalized muscular
weakness, abobotulinumtoxinA 1,500 U).
During the open-label extension, TEAE incidence
decreased across cycles with both doses (table 3), con-
sidering that most participants leaving between cycles
had reached maximal study duration (figure 1). Most
TEAEs were mild to moderate. Falls and muscular
weakness were reported (table e-9) with 9/345 par-
ticipants (2.6%) presenting fractures following falls
across all open-label cycles. Nineteen participants
withdrew due to TEAEs; 11 were considered
treatment-related. SAEs were experienced by 11%
of participants across all cycles. There were 2 deaths
(suicide and respiratory failure; both abobotulinum-
toxinA 1,500 U), neither considered treatment-related.
Four participants treated with abobotulinumtoxinA
1,500 U reported 5 SAEs suggestive of remote toxin
spread (3 generalized muscular weaknesses, 2 dys-
phagia; e-Results); 1 participant withdrew as
a result, 1 (2 SAEs) was reinjected at 2 consecutive
treatment cycles, and 2 withdrew for independent
reasons.
There were no significant hematology or clinical
biochemistry changes and no clinically significant
changes in vital signs or ECG measures. No partici-
pant presented with seroconversion for neutralizing
antibodies (baseline antibodies reported in e-Results).
DISCUSSION In this large, international, multicen-
ter, dose-ranging, placebo-controlled study of abo-
botulinumtoxinA in chronic hemiparesis, a single
injection of abobotulinumtoxinA 1,500 U signifi-
cantly reduced muscle tone (MAS GSC) at weeks 4
(p 5 0.009) and 12 (p 5 0.03). No significant effect
on PGA was seen in preplanned analyses, nor was
a significant difference seen between abobotuli-
numtoxinA and placebo on walking speed improve-
ment after a single treatment cycle.
In the double-blind phase, a 0.05 m/s walking
speed increase was observed with placebo, consistent
with previous placebo-controlled studies of botuli-
num toxin in hemiparesis (10.04 m/s and 10.03
m/s with placebo at week 4).17,18 Subsequent walking
speed changes observed here should be interpreted
with caution; no study has evaluated repeated placebo
injections. Yet, while the degree of significance for
PGA difference between abobotulinumtoxinA and
Figure 2 Main efficacy results (abobotulinumtoxinA [ABO] doses combined)
(A) Gastrocnemius–soleus complex (GSC) Modified Ashworth scale (MAS) and (B) physician
global assessment (PGA) mean scores at baseline or week 4 and across treatment cycles and
(C) mean change in comfortable barefoot walking speed from baseline and week 4 and week
12 of each cycle. Baseline refers to baseline of double-blind study, prior to first injection.
Error bars in A and B show SD. aPercentage improvement from baseline. bA post hoc analysis
compared change from baseline in 10-m walking speed at week 4 vs week 12 across cycles
using a model for repeated measures; greater improvement was observed at week 12
compared with week 4 across cycles. DB 5 double-blind study; LS 5 least-squared; PBO 5
placebo.
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placebo was p 5 0.06 in the planned analysis, signif-
icant PGA improvement (p 5 0.04) was shown with
both abobotulinumtoxinA doses in nonparametric
post hoc analyses.
In the open-label extension, repeated abobotuli-
numtoxinA injections (both doses) were well-
tolerated over 1 year and associated with progressive
improvements in PGA, spasticity (angle of catch),
active range of dorsiflexion, walking speed, and
QoL. These continuing functional improvements
occurred while muscle tone and passive range of
motion stabilized beyond the third injection. Across
cycles, 15%–32% of participants did not need rein-
jection at week 12.
In the open-label study, mean decrease from base-
line in MAS score reached11 by cycle 2 week 4 with
both abobotulinumtoxinA doses. MAS and XV1 sta-
bilization beyond this time point may reflect residual
structural changes in calf muscles insensitive to
BoNT, as suggested by $20% CS.16,19 In contrast,
continuing improvements in angle of catch and active
dorsiflexion may represent increasing extinction of
motor units recruited in response to fast stretch
(XV3) and co-contraction (XA) with repeated BoNT
injections.
Walking speed normally plateaus at ;0.7 m/s in
chronic (.9 months) poststroke hemiparesis.4,20,21 Of
136 participants treated for 4 cycles, 16% achieved
walking speed .0.8 m/s (vs 0% at baseline), a thresh-
old associated with community mobility.15 This walk-
ing speed improvement paralleled gradual increases in
PGA (physician-rated) and QoL (participant-rated).
Walking speed improvement was consistently greater
at week 12 than week 4, contrasting with other out-
come measures and prior placebo-controlled BoNT
studies,8,10,13 probably linked to the functional nature
of this outcome. Twenty-five percent walking speed
increase and 16% of participants reaching full commu-
nity mobility are meaningful achievements in chronic
hemiparesis, improving QoL.15,22,23 While modest ef-
fects on walking speed/active range of dorsiflexion
occurred 4 weeks after a single injection (double-blind
study), the correlated improvements in walking speed
and active dorsiflexion, knee extended (table e-10) after
1 year of repeated injections may correspond to cumu-
lative effect over time and the need for accommodation
periods while participants adapt their walking pattern
with reduced co-contraction and increased range of
motion produced by abobotulinumtoxinA.
Lower limb multilevel injections in distal (mainly
gastrocnemius, soleus, tibialis posterior) or proximal
muscles (e.g., hamstrings, adductors) with both abo-
botulinumtoxinA doses were well-tolerated over
repeated, open-label cycles, with an expected safety
profile based on previous experience.10,11
Open-label extension efficacy data should be con-
sidered in the context of no placebo comparator and
increasingly smaller participant numbers because of
study completion or withdrawals. Yet the discrepancy
between some outcome measures that reach a plateau
of improvement (mostly passive outcomes) long
before others (mostly active or functional outcomes)
Table 3 Summary of treatment-emergent adverse events (TEAEs) following abobotulinumtoxinA injections at any cycle (safety population)
Events, n (%) (number of events) Double-blind
Open-label
Cycle 1 Cycle 2 Cycle 3 Cycle 4
Placebo n 5 130
TEAEs 41 (31.5) (94) — — — —
Treatment-related TEAEs 8 (6.2) (13) — — — —
Treatment-emergent AESIs 7 (5.4) (7) — — — —
SAEs 7 (5.4) (9) — — — —
ABO 1,000 U (LL) n 5 127 n 5 10 n 5 65 n 5 133 n 5 88
TEAEs 55 (43.3) (112) 4 (40.0) (6) 23 (35.4) (47) 37 (27.8) (79) 15 (17.0) (33)
Treatment-related TEAEs 15 (11.8) (18) 1 (10.0) (1) 6 (9.2) (8) 6 (4.5) (9) 3 (3.4) (5)
Treatment-emergent AESIs 6 (4.7) (8) 1 (10.0) (1) 2 (3.1) (2) 8 (6.0) (9) 3 (3.4) (5)
SAEs 5 (3.9) (5) 0 (0.0) (0) 0 (0.0) (0) 5 (3.8) (5) 2 (2.3) (4)
ABO 1,500 U (LL) n 5 128 n 5 335 n 5 232 n 5 91 n 5 51
TEAEs 52 (40.6) (109) 136 (40.6) (284) 74 (31.9) (157) 10 (11.0) (18) 6 (11.8) (14)
Treatment-related TEAEs 16 (12.5) (27) 42 (12.5) (61) 17 (7.3) (31) 1 (1.1) (1) 2 (3.9) (3)
Treatment-emergent AESI 13 (10.2) (16) 30 (9.0) (34) 22 (9.5) (24) 2 (2.2) (2) 2 (3.9) (2)
SAEs 5 (3.9) (6) 23 (6.9) (30) 14 (6.0) (16) 2 (2.2) (2) 0 (0.0) (0)
Abbreviations: ABO 5 abobotulinumtoxinA; AESI 5 adverse event of special interest; LL 5 lower limb; SAE 5 serious adverse event.
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remains a compelling observation in chronic spastic
paresis. Finally, participant-centered interviews on
ambulation performance in daily life could have opti-
mized evaluation.23
Regarding optimal dosing to treat adult lower limb
spastic paresis, although only the 1,500 U dose pro-
duced a significant effect on the primary outcome,
both doses showed significant differences vs placebo
in soleus alone. In addition, results after repeated in-
jections were similar across both doses. Taking these
data together, doses up to 1,500 U should probably
be considered for adult patients with lower limb spas-
tic paresis, tailored to individual patient impairment
and treatment objectives. Considering maximal
approved abobotulinumtoxinA dosing by different
countries for adult upper and lower extremities, the
remaining dose not used in the lower limb could be
used for the upper limb, depending on patient prior-
ities and needs.13
A single injection of abobotulinumtoxinA reduced
muscle tone (MAS GSC) in participants with chronic
hemiparesis. Passive outcome measure improvements
(muscle tone), demonstrated after a single abobotuli-
numtoxinA injection, stabilized over time. While
PGA and walking speed were not significantly
improved compared with placebo in preplanned
double-blind analysis (PGA was significantly improved
in post hoc nonparametric analysis), continuous walk-
ing speed, PGA, andQoL improvements were observed
over 1 year of open-label, repeated abobotulinumtoxi-
nA administration, with 16% reaching a walking speed
range associated with capacity for achieving community
ambulation. This is the first report of such functional
improvements in gait and QoL in this chronic popula-
tion with repeated abobotulinumtoxinA injections
(open-label study), and moreover, in the absence of
a protocol-defined, standardized, physiotherapy regi-
men. Repeated abobotulinumtoxinA injections com-
bined with a tailored rehabilitation program should
be studied to determine whether even greater improve-
ments over time could occur in chronic hemiparesis.
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